18F-Prostate Specific Membrane Antigen PET-CT as a potential novel imaging modality for pancreatic cancer: A pilot study (PANSCAN-2) - PANSCAN-2

Vrije Universiteit Medisch Centrum0 个研究点目标入组 15 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•- Patients aged 18 years or older
•- Diagnosis of suspected pancreatic ductal adenocarcinoma and eligible for
•- Before patient registration, written informed consent must be given according
•to ICH/GCP, and national/local regulations.

•- Patients with metastatic PC will be excluded, as current guidelines exclude
•them from surgery because of no survival benefit.
•- Women who are pregnant and/or or lactating.
•- Medical or psychiatric conditions that compromise the patient*s ability to
•give informed consent. Presence of any psychological, familial, sociological or
•geographical condition potentially hampering compliance with the study protocol
•and follow-up schedule.
•- Prior radiotherapy to the abdomen and/or thorax.
•- Unacceptable known (clinically significant) cardiovascular or pulmonary
•disease, renal or liver dysfunction, which could hamper participation in this
•study or jeopardize the patients* health.
•- Known hypersensitivity to drugs comparative to 18F-PSMA, or any of their
•excipients or to any component of 18F-PSMA.
•- Inability to undergo PET/CT scanning (e.g. claustrophobia, weight limits or
•inability to tolerate lying for the duration of a PET/CT scan (~30 min).
•- Inability to undergo routine MRI or CT scans as part of the diagnostic work

发起方